Stock Market logoStock Market Station

All the stock market news, every minute updated!

28 July 2021
17:51 hour

J&J forecasts $2.5 billion in 2021 COVID-19 vaccine sales, sets lower production target

Investing.com

21/07/2021 - 18:32


READ THE FULL ARTICLE ON INVESTING.COM

Related headlines:

  1. Govt sets record target to raise foodgrain production by 2% during 2021-22 (01/05/2021 - Financial Express)
    The government has set a target to buy 42.74 MT for the central pool during 2021, which is nearly 10% more than actual quantity purchased last year.
    [visit article]
  2. : Moderna in bid to double COVID-19 vaccine production to up to 3 billion doses in 2022 (29/04/2021 - Market Watch)
    The U.S. biotech also raised its manufacturing forecast for 2021 to 800 million to 1 billion doses.
    [visit article]
  3. ONGC: Gas output may clock 6% CAGR over FY20-23 (17/02/2021 - Financial Express)
    ONGC reported in-line sales volumes, with realisation at $43.2/bbl. Crude oil production has reached last year’s levels, while gas is still marginally lower YoY due to lower offtake by customers on account of Covid-19. For FY21/FY22, the company has guided for oil production at ~22.5mmt/23mmt (flat YoY), while gas production is set to increase to […]
    [visit article]
  4. Moderna (MRNA): COVID-19 vaccine helps company deliver first ever profitable quarter (06/05/2021 - AlphaStreet)
    Shares of Moderna Inc. (NASDAQ: MRNA) were down 3% in morning hours on Thursday despite the company reporting the first profitable quarter in its history. Moderna delivered an earnings surprise for the first quarter of 2021 that smashed analysts’ projections of a loss. However, despite seeing a sharp rise year-over-year, revenues fell short of expectations. The top line miss combined with fears over easing of patent protections on coronavirus vaccines took a toll on the stock. Strong Q1 Total revenue jumped to $1.9 billion in Q1 from $8 million in the same period last year, driven by sales of the COVID-19 vaccine. Product sales amounted to $1.7 billion from sales of the vaccine. The company reported net income of $1.2 billion, or $2.84 per share, in the quarter compared to a loss of $124 million, or $0.35 per share, in the same period last year. COVID-19 vaccine Moderna announced data that shows that a booster dose of its vaccine is effective against both the coronavirus as well as two of its variants. The company also announced positive data from its trial on teenagers that indicated a 96% efficacy rate in those aged between 12-17 years. Moderna now expects to supply 800 million to 1 billion doses of its COVID-19 vaccine in 2021 and it is making additional investments to increase its global supply to up to 3 billion doses in 2022. The company has signed Advance Purchase Agreements (APAs) for the delivery of its vaccine in 2021, which is anticipated to rake in $19.2 billion in product sales, including sales recorded in Q1. Moderna expects to deliver 200-250 million doses in the second quarter of 2021. Moderna has signed APAs with Israel and Switzerland for 2022, with Switzerland having options for further deliveries in 2023. Through its recent agreement, the company has committed up to 466 million doses to COVAX for 2022. The company is discussing the extension of its APAs to 2022 for all the countries with existing APAs for this year as well as the option to supply new geographies in Asia, Latin America and Africa in 2022 where it was unable to do so this year due to manufacturing supply constraints. Stock The stock has gained 198% in the past 12 months and 52% since the beginning of this year. Pharma stocks fell on news of the US government’s agreement to waiver patent protection rules on COVID-19 vaccines in order to allow easier production and supply around the world. This has raised concerns over the impact of this move on the revenue and profits of pharma companies. Click here to read more on pharma stocks The post Moderna (MRNA): COVID-19 vaccine helps company deliver first ever profitable quarter first appeared on AlphaStreet.
    [visit article]
  5. : National Retail Federation forecasts 2021 retail sales growth between 6.5% and 8.2% as COVID-19 vaccine continues roll out (24/02/2021 - Market Watch)
    The economy is expected to grow at the fastest pace in 20 years, according to NRF.
    [visit article]
  6. : National Retail Federation forecasts 2021 retail sales growth between 6.5% and 8.2% as COVID-19 vaccine continues roll out (24/02/2021 - Market Watch)
    The economy is expected to grow at the fastest pace in 20 years, according to NRF.
    [visit article]
  7. The Wall Street Journal: U.S. production of COVID-19 vaccine dramatically speeds up (22/03/2021 - Market Watch)
    COVID-19 vaccine manufacturers are ramping up production, churning out far more doses a week than earlier in the year, progress that is accelerating mass vaccination campaigns in the U.S.
    [visit article]
  8. Covid-19 vaccine: States must not protest Covishield pricing (26/04/2021 - Financial Express)
    Price-capping will affect vaccine production, innovation; central procurement at lower price helps them in any case
    [visit article]
  9. Target earnings top estimates as sales jump 21%, boosted by strong holiday season, stimulus checks (02/03/2021 - Reddit Stocks)
    https://www.cnbc.com/2021/03/02/target-tgt-earnings-q4-2020.html Earnings per share: $2.67 adjusted vs. $2.54 expected Revenue: $28.34 billion vs. $27.48 billion expected Comparable sales, a key metric that tracks sales at stores open at least 13 months and online, rose 20.5% compared with a year earlier, as digital comparable sales rose by 118% year over year. That surpassed the 16.8% comparable sales growth that analysts expected, according to StreetAccount. Target is a good non tech and recovery stock. Recently I just notice that a target is opening near my area, it is expanding smoothly. With the stimulus check coming and people starting to go out to shopping, target definitely will benefit and the stock will reward the shareholders.   submitted by   /u/coolcomfort123 [link]   [comments]
    [visit article]
  10. Covid-19 vaccine: Centre has not contracted all SII production (23/04/2021 - Financial Express)
    State governments are free to procure the vaccine doses from the vaccine manufacturers as per the Liberalised Pricing and Accelerated National Covid-19 Vaccination Strategy.
    [visit article]
  11. US retail sales forecasted to rise 6.5-8.2% on vaccine roll-out and pent-up demand (24/02/2021 - AlphaStreet)
    US retail sales are projected to grow between 6.5% and 8.2% to more than $4.33 trillion in 2021. According to the National Retail Federation’s annual forecast, pent-up demand, vaccine distribution and healthy consumer fundamentals are projected to drive higher economic growth, retail sales and consumer spending. In 2021, NRF projects retail sales to range between $4.33 trillion and $4.4 trillion. Of this, online sales are expected to grow 18-23% to $1.14 trillion to $1.19 trillion. The COVID-19 pandemic drove a rapid shift to ecommerce during 2020 causing many retailers to accelerate their digital transformation over a couple of months which otherwise would have taken a few years. Retailers saw their digital sales surge, particularly during the holiday season as people did more of their holiday shopping online. The report states that retail sales rose 6.7% year-over-year to $4.06 trillion in 2020 in spite of the pandemic. This number was higher than the 3.9% growth seen in 2019, and nearly double the growth of at least 3.5% forecasted by NRF, without accounting for a global health crisis. This growth was driven by an increase of around 22% in online sales to $969.4 billion. NRF said the November-December holiday period in 2020 saw strong growth with retail sales increasing 8% to $787.1 billion. Holiday sales comprised 19.4% of overall annual retail sales. Online sales represented $206.9 billion of total holiday sales, reflecting a year-over-year growth of 22.6%. The trade group forecasts real GDP growth of 4.5-5% in 2021 and also expects the economy to gain between 220,000 and 300,000 jobs per month during the year depending on the pace of the economy in the second and third quarters. “The trajectory of the economy is predicated on the effectiveness of the vaccine and its distribution. Our principal assumption is that that the vaccination will be effective and permits accelerated growth during the mid-year. The economy is expected to see its fastest growth in over two decades.” – NRF Chief Economist Jack Kleinhenz   Mr. Kleinhenz added that factors such as savings, higher home prices, high stock valuations, more government support and low interest rates influence the economy and consumer spending behavior. He said that once things gradually normalize, people will turn to services, which normally account for 70% of consumer spending. Click here to read more retail newsThe post US retail sales forecasted to rise 6.5-8.2% on vaccine roll-out and pent-up demand first appeared on AlphaStreet.
    [visit article]
  12. The Wall Street Journal: Moderna plans to expand production of COVID-19 vaccine boosters, supply more countries (21/06/2021 - Market Watch)
    Moderna Inc. is adding two new production lines at the rebuilt former Polaroid plant where it manufactures its COVID-19 vaccine, part of a push to prepare for making booster shots and the future of the pandemic
    [visit article]
  13. Pfizer lifts sales forecast for COVID-19 vaccine to $26 billion (04/05/2021 - Investing.com)

    [visit article]
  14. Target Corp. (TGT) Q1 Earnings: Key financials and quarterly highlights (19/05/2021 - AlphaStreet)
    Target Corporation (NYSE: TGT) reported first quarter 2021 earnings results today. Total revenue increased 23.4% year-over-year to $24.1 billion. GAAP net income jumped more than 600% to $2 billion, or $4.17 per share, compared to last year. Adjusted EPS gained 525% year-over-year to $3.69. For the second quarter of 2021, Target expects mid to high single digit growth in comparable sales, and for the last two quarters of the year, the company estimates comparable sales to see positive single digit growth. (This story will be updated shortly with an infographic)The post Target Corp. (TGT) Q1 Earnings: Key financials and quarterly highlights first appeared on AlphaStreet.
    [visit article]
  15. Target sales jump 23% as exclusive brands, curbside pickup draw in shoppers (19/05/2021 - Reddit Stocks)
    https://www.cnbc.com/2021/05/19/target-tgt-q1-2021-earnings.html Earnings per share: $3.69 adjusted vs. $2.25, expected Revenue: $24.20 billion vs. $21.81 billion, expected At Target’s stores and on its website, traffic grew by 17% and basket size grew by 5% in the three-month period compared with a year earlier. The big EPS beats is showing that Target is operating perfectly. It is a good non-tech stock that investors should be buying and it is winning the retail war. The e-commerce is growing and it is getting more market share to compete with amazon.   submitted by   /u/coolcomfort123 [link]   [comments]
    [visit article]
  16. Ovintiv ticks lower after Q2 loss; sets new debt reduction target (28/07/2021 - Seeking Alpha)

    [visit article]
  17. : Moderna’s first-ever profit and billion-dollar quarter is dampened by COVID-19 vaccine patent proposal (07/05/2021 - Market Watch)
    It's been a complicated day for Moderna Inc. as the company reported its first-ever profit and its first-ever billion dollars in sales amidst an unprecedented move by the Biden administration to support waiving patent rights for COVID-19 vaccines.
    [visit article]
  18. : Moderna’s first-ever profit and billion-dollar quarter is dampened by COVID-19 vaccine patent proposal (06/05/2021 - Market Watch)
    It's been a complicated day for Moderna Inc. as the company reported its first-ever profit and its first-ever billion dollars in sales amidst an unprecedented move by the Biden administration to support waiving patent rights for COVID-19 vaccines.
    [visit article]
  19. J&J reports $100 million in vaccine sales as results top forecasts (20/04/2021 - Investing.com)

    [visit article]
  20. UK sets July-end target for anti-COVID jabs for all adults (21/02/2021 - Financial Express)
    The new pledge comes as the UK has met its February 15 target to cover the most vulnerable categories in the top four JCVI categories over the elderly and frontline workers.
    [visit article]
  21. Market Extra: J&J debt trades lower after pause of one-shot COVID-19 vaccine (13/04/2021 - Market Watch)
    Johnson & Johnson's corporate bonds are trading lower across the board Tuesday, after two leading U.S. health agencies recommended a pause on its one-shot COVID-19 vaccine after six vaccinated women developed blood clotting.
    [visit article]
  22. Moderna (MRNA) to increase vaccine supply capacity and accelerate pipeline investments (25/02/2021 - AlphaStreet)
    Shares of Moderna Inc. (NASDAQ: MRNA) were up 6% in morning trade on Thursday after the company reported its fourth quarter and full year 2020 earnings results. Revenues surpassed market estimates but the quarterly loss came in wider than expected. The stock has gained 46% since the beginning of this year and 486% over the past 12 months. Quarterly numbers Moderna generated $571 million in total revenue in Q4 2020 compared to revenues of $14 million in Q4 2019. The top line growth was driven by increases in grant revenue and product sales. The company began recognizing revenue from its COVID-19 vaccine in December following its approvals in the US and Canada. Net loss amounted to $272 million, or $0.69 per share, compared to a loss of $123 million, or $0.37 per share, in the year-ago period. COVID-19 vaccine Moderna has raised the lower end of its 2021 global manufacturing plan to 700 million doses from 600 million doses, and it is still working on its plan to supply up to 1 billion doses in 2021. Owing to high global demand, the company is making new capital investments to increase capacity up to 1.4 billion doses in 2022. The company has completed the manufacturing of clinical trial material for its vaccine candidate against the South Africa variant of the virus. Doses have been shipped to the National Institutes of Health for a Phase 1 clinical trial. Moderna has supply agreements with various countries around the world for its COVID-19 vaccine. The company has agreed to supply 300 million doses to the US government with options for another 200 million doses. The company will supply 310 million doses to the European Union with the option for another 150 million doses in 2022. Moderna also has agreements with countries like Japan, Canada, the UK, Switzerland, Republic of Korea, Israel, Taiwan and Singapore for the supply of the COVID-19 vaccine. Moderna expects to garner $18.4 billion from COVID-19 vaccine sales this year. The company has signed advance purchase agreements (APAs) for delivery in 2021 and is in discussions with various governments on APAs for deliveries in 2021 and 2022. Management update Moderna announced that its Chief Medical Officer, Tal Zaks, will depart from the company in late September after six years of service. The company is searching for a suitable successor. Pipeline Moderna is working on several vaccine candidates in its infectious diseases and rare diseases portfolio. These include vaccines against the seasonal flu, which affects approx. 8% of the US population each year and presents an average economic burden of approx. $11 billion per year, as well as the HIV, Nipah and Zika viruses. Click here to access the transcripts of the latest earnings conference callsThe post Moderna (MRNA) to increase vaccine supply capacity and accelerate pipeline investments first appeared on AlphaStreet.
    [visit article]
  23. Coronavirus Update: Covax gets $2.4 billion in COVID vaccine supply commitments for world’s poorest countries as experts warn on variants (03/06/2021 - Market Watch)
    The global tally of COVID-19 cases neared 172 million on Thursday, and the number of vaccines administered edged closer to 2 billion, a day after a summit ended with pledges of $2.4 billion to the Covax program that aims to secure vaccine supply for the world's poorest countries.
    [visit article]
  24. The Wall Street Journal: Novavax delays its COVID-19 vaccine timeline (11/05/2021 - Market Watch)
    Novavax Inc. has delayed plans to seek regulatory clearances for its COVID-19 vaccine, while shortages in raw materials are slowing the ramp-up of production of doses, the company said.
    [visit article]
  25. NewsWatch: CDC committee to meet on J&J COVID vaccine as India sets record case number for second straight day (23/04/2021 - Market Watch)
    The global tally of confirmed cases of the coronavirus-borne illness COVID-19 was headed toward 145 million on Friday, as a Centers for Disease Control and Prevention advisory committee was scheduled to convene to make a decision on the fate of the Johnson & Johnson vaccine, after it was linked to a rare blood-clotting disorder.
    [visit article]
  26. CDC sets emergency meeting next week; likely to discuss Pfizer/BIonTech COVID-19 vaccine on adolescents (05/05/2021 - Seeking Alpha)

    [visit article]
  27. Cannabis Watch: Curaleaf’s strong quarter sets it up for a better-than-expected year — and that’s without sales in New York and New Jersey (11/05/2021 - Market Watch)
    Curaleaf Holdings Inc.'s stronger-than-expected first-quarter earnings have put the company on track to deliver above-consensus numbers for 2021 and beat its own guidance for full-year revenue of $1.2 billion to $1.3 billion, analysts said Tuesday.
    [visit article]
  28. : Pfizer’s next play: A vaccine maker and pandemic ‘partner’ to governments (04/05/2021 - Market Watch)
    Pfizer Inc.’s COVID-19 vaccine is on track to generate a whopping $26 billion in sales this year, making it the drug maker’s top-selling drug and forging a new path into infectious diseases for the legacy drug maker.
    [visit article]
  29. Coronavirus Update: EU expects to take delivery of 1 billion COVID-19 vaccine doses by end-September, agrees on digital certificate for travelers (25/05/2021 - Market Watch)
    The European Union, which has been lagging in getting its 450 million citizens vaccinated against COVID-19, expects to take delivery of 1 billion vaccine doses by end-September, propelling it past its goal of inoculating at least 70% of its population by late summer.
    [visit article]
  30. : Moderna vows to double COVID-19 vaccine capacity by next year (24/02/2021 - Market Watch)
    Moderna said it plans on boosting COVID-19 vaccine to 1.4 billion doses by 2022.
    [visit article]
  31. Coronavirus Update: CDC committee to meet on J&J COVID vaccine as India sets record case number for second straight day (23/04/2021 - Market Watch)
    The global tally of confirmed cases of the coronavirus-borne illness COVID-19 was headed toward 145 million on Friday, as a Centers for Disease Control and Prevention advisory committee was scheduled to convene to make a decision on the fate of the Johnson & Johnson vaccine, after it was linked to a rare blood-clotting disorder.
    [visit article]
  32. Coronavirus Update: CDC committee to meet on J&J COVID vaccine as India sets record case number for second straight day (23/04/2021 - Market Watch)
    The global tally of confirmed cases of the coronavirus-borne illness COVID-19 was headed toward 145 million on Friday, as a Centers for Disease Control and Prevention advisory committee was scheduled to convene to make a decision on the fate of the Johnson & Johnson vaccine, after it was linked to a rare blood-clotting disorder.
    [visit article]
  33. Housing sales more resilient to Covid disruptions in Q2 2021 (06/07/2021 - Financial Express)
    Housing sales in Q2 grew 83% year-on-year on a lower base to 19,365 units. However, sequentially, sales declined 23% from 25,583 units in January-March 2021.
    [visit article]
  34. China sets growth target of more than 6% for 2021 (05/03/2021 - Seeking Alpha)

    [visit article]
  35. China sets 2021 GDP growth target at more than 6% (05/03/2021 - Investing.com)

    [visit article]
  36. US eyes joint production of Johnson and Johnson Covid vaccine in India, in touch with Serum Institute (12/05/2021 - Financial Express)
    The White House, last month, had said the United States plans to share AstraZeneca covid vaccine's 60 million doses globally as soon as they become available, and a significant chunk of the stockpile is being expected by India.
    [visit article]
  37. Israeli Health Officials Expect Biannual Vaccinations (04/05/2021 - Reddit Stocks)
    2022 and 2023 Vaccine Purchases Delayed as Israeli Health Officials Expect Biannual Vaccinations [Sauze] Sources involved in the purchase of additional vaccines on Wednesday morning responded to the claim that Israel may be stuck with excess vaccine doses and told Israel Hayom that it will be necessary to vaccinate the entire population every six months. As to the criticism of the high cost of the vaccines, which several Israeli news outlets put at NIS 3.5 billion ($1.05 billion), those same sources said the real cost is lower. But they supported the position that the purchase of 36 million new vaccines is needed, because the vaccine may be given every six months, in two doses each time, with the expectation that in the near future young people under 16 will also be vaccinated. Holy shit! And they are already ordering for 2024! https://www.ctvnews.ca/health/coronavirus/ottawa-inks-deal-with-pfizer-for-millions-of-covid-19-booster-shots-through-2024-1.5399696 And pfizer vaccine storable in standard freezer! https://medicalxpress.com/news/2021-04-pfizer-ceo-vaccine-easier-ship.html   submitted by   /u/BareAuthority [link]   [comments]
    [visit article]
  38. A look back at Amazon Prime Day growth. (21/06/2021 - Reddit Stocks)
    2015 (The first Prime Day) - Estimated sales: $900,000 2016 - Estimated sales: $1.5 billion 2017 - Estimated sales: $2.4 billion 2018 - Estimated sales: $4.2 billion 2019 - Estimated sales: $7.2 billion 2020 - Estimated sales: $13.9 billion Source: https://www.nbcnews.com/shopping/amazon-prime-day/amazon-prime-day-history-n1269819   submitted by   /u/Karnes [link]   [comments]
    [visit article]
  39. Pfizer raises 2021 guidance above expectations on strong COVID-19 vaccine sales (28/07/2021 - Seeking Alpha)

    [visit article]
  40. BioNTech trades higher after raising 2021 guidance for COVID-19 vaccine sales (10/05/2021 - Seeking Alpha)

    [visit article]
  41. Coronavirus Update: U.S. tops 30 million confirmed cases of COVID-19 as Biden pledges $10 billion investment in expanding vaccine access (25/03/2021 - Market Watch)
    The U.S. case tally for confirmed cases of the coronavirus-borne illness COVID-19 climbed above 30 million on Thursday, as President Joe Biden unveiled a $10 billion program that aims to ensure vaccine access for the hardest-hit and most-at-risk communities across the U.S.
    [visit article]
  42. Tesla's China sales more than doubled in 2020 (09/02/2021 - Reddit Stocks)
    https://www.cnbc.com/2021/02/09/teslas-china-sales-more-than-doubled-in-2020.html Tesla's sales in China more than doubled last year to $6.66 billion, according to a filing out Monday. That's about one-fifth of Tesla's sales overall, a far greater proportion than the 12% in 2019. The electric car maker has been ramping up production at its factory in Shanghai and selling China-made vehicles to the local market.   submitted by   /u/coolcomfort123 [link]   [comments]
    [visit article]
  43. When will Covid 19 vaccine become available in the market? AIIMS Director shares expected timeline (17/02/2021 - Financial Express)
    Covid-19 India Vaccine Update: Till 8:00 AM today, around 90 lakh healthcare and frontline workers have been inoculated with the Covid-19 vaccine in the country.
    [visit article]
  44. Patent-waivers or pandemic: The EU must not block patent-waivers for Covid vaccines (05/07/2021 - Financial Express)
    As per Bloomberg Vaccine Tracker, close to 3.2 billion Covid vaccine-doses have been administered till July 4, but the wealthiest nations and regions are receiving the shots more than 30 times faster than the poorest.
    [visit article]
  45. COVID-19: Whie House refuses to comment on lifting ban on vaccine raw materials export to India (20/04/2021 - Financial Express)
    The White House on Monday did not respond to questions on the request by Serum Institute of India to lift export ban on certain raw materials needed for ramping up production of COVID-19 vaccine
    [visit article]
  46. Back to the Basics - Tesla (03/07/2021 - Reddit Stock Market)
    Check out our Tesla model here: https://thinklikeananalyst-my.sharepoint.com/:x:/p/theanalyst/EXpJOebEvnFGjBOeQ1mQZm0BARiHpN8-T2dSiItdEDHgjQ?download=1 I'm not the first to say this but at 600x trailing earnings, Tesla ‘feels’ expensive. Sure the Tesla story is compelling, and their execution of late has been impressive, but still: what does 600x earnings even mean, and how are we supposed to make sense of this number? Well the answer is that you have to go back to the basics, and look at the fundamentals. Specifically, it means trying to put some actual numbers to the story, so you see what it all adds up to. And the best way to do this is with a model. We’ve built a very simple model for Tesla to see if we can make sense of its valuation. The model is very simple and has just three forecast variables: revenue growth, operating margin, and capital turns (which measure how efficiently the company utilizes its capital). These three variables are all we need to do our analysis. What we’ve specifically tried to model out is what kind of financial performance Tesla would have to deliver in order to justify its current share price. This means playing with my three forecasts variables until I get to $600. I’ve used consensus revenue forecasts over the next two years as a starting point, and then proceeded from there. Note that consensus revenue estimates for Tesla are $49.1 billion for 2021, and $65.7 billion for 2022. This is extraordinary, and represents growth rates of 55% and 34% over the next two years. These growth rates don’t seem sustainable, so beyond 2022, I’ve trended revenue growth rates down to 20% and carried this forward. I should point out that for capital intensive businesses like Tesla, revenue growth, especially at these levels, is never free, because it requires a company to continually reinvest in the business. For Tesla, it means continually investing in additional production capacity in order to meet production and sales targets. You will see this reflected in our cash flow forecasts, where annual capex requirements means negative cash flows for the first few years . In terms of margins, Tesla has seen steady improvement over the last few years as it scales up, and there’s no reason to think they can’t continue to improve margins further. Tesla is after all a premium brand, and commands premium pricing. Nevertheless, the EV space is attracting a lot of new players and a lot of new investment, and this will likely put a cap on Tesla’s margin expansion into the future. For modelling purposes, our NOPAT margin variable is our key lever, and we’ve had to ramp this up very aggressively to hit our $600 target. Tesla’s NOPAT margin is currently around 5%, but we’ve had to gradually move this up to 18.5% over the next few years. Now the comps we’ve selected aren’t perfect, but you will notice that at these levels, Tesla’s NOPAT margin would be well above industry benchmarks. You will also notice that our forecasts generate an ROIC (return on invested capital) of almost 33% at its peak, again well above industry standards.   submitted by   /u/thinklikeananalyst [link]   [comments]
    [visit article]
  47. : Trump says he recommends COVID-19 vaccine: ‘It’s a great vaccine and it’s a safe vaccine’ (17/03/2021 - Market Watch)
    Former President Donald Trump on Wednesday recommended the COVID-19 vaccine to his supporters, amid concerning recent polls showing Republicans are less likely to get vaccinated.
    [visit article]
  48. Govt aid will help vaccine production, says Poonawalla (21/04/2021 - Financial Express)
    The government has announced assistance of Rs 4,500 crore to SII and Bharat Biotech to ramp up vaccine production. SII will get Rs 3,000 crore through credit support, reported to be an advance for vaccine supplies till July. Bharat Biotech will get Rs 1,500 crore.
    [visit article]
  49. Unemployment surges to 10.72% amid COVID-19 pandemic; digital upskilling may help revive job market (15/05/2021 - Financial Express)
    One effect of Covid has been accelerated digital adoption- over 500 million people in India, from lower rungs of the socio-economic pyramid, will have acquired new digital skill sets by 2022
    [visit article]

For more information mailto [email protected]. Disclaimer.